Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells

Crizotinib was a first generation of ALK tyrosine kinase inhibitor approved for the treatment of ALK-positive non-small-cell lung carcinoma (NSCLC) patients. COMPARE and cluster analyses of transcriptomic data of the NCI cell line panel indicated that genes with different cellular functions regulate...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulos, Joelle C., Saeed, Mohamed E. M., Chatterjee, Manik, Bülbül, Yagmur, Crudo, Francesco, Marko, Doris, Munder, Markus, Klauck, Sabine M., Efferth, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617756/
https://www.ncbi.nlm.nih.gov/pubmed/34832908
http://dx.doi.org/10.3390/ph14111126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617756/
https://www.ncbi.nlm.nih.gov/pubmed/34832908
http://dx.doi.org/10.3390/ph14111126

Ejemplares similares